BETA DRUGS LIMITED

Beta Drugs Ltd. bags yet another DCGI approval for its new drug; KABONIB after MDS-O

Beta Drugs Ltd (BDL) has developed an in-house Cabozantinib under the brand name KABONIB and received approval from the Drug Controller General of India (DCGI) to manufacture its API & formulation.

After the DCGI approval of MDS-O & KABONIB, the company is seeking DCGI approval for its upcoming new formulations and APIs to be launched in the Indian market.

The company is continuously strengthening its position in both the formulation & API market and expects to launch many novel FTLs in the next 1-2 years.

Now with the launch of KABONIB, the company has further strengthened its product basket in the Kidney cancer (RCC) portfolio, which includes ADTRINIB(Sorafenib), ADSUNIB(Sunitinib), BEXINIB(Axitinib) & PAZOTAB(Pazopanib)

Recently, USFDA has approved Cabozantinib as 1st line treatment in advanced RCC due to its better efficacy and safety over current therapies. Despite its efficacy, the high cost of therapy leads to the restricted use of this drug in India.

However, BDL has launched KABONIB at a very affordable price for Indian patients to increase accessibility and improve patient compliance. It is available in 20mg/40mg/60mg strengths.

Cabozantinib has huge scope in the Indian market, expected to have a roughly 30 Cr market in FY22-23. It is not used in advanced Renal Cell Carcinoma but has a great scope in Hepatocellular Carcinoma and metastatic medullary thyroid cancer.

In this fiscal year, the company is introducing Carfilzomib & many more novel molecules.

BETA DRUGS LTD BADDI (H.P.)

CIN No.: L24230HP2005PLC028969

Admin. Office : SCO 184, Sector-5, Panchkula-134 114 Haryana (INDIA) Phone: +91-172-2585481-482-483

Registered Office & Works: Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

Website :- www.betadrugslimited.com | **E-Mail :-** info@betadrugslimited.com